Pregnancy After Breast Cancer Not Linked to Recurrence or Death from the Disease

Publication
Article
OncologyONCOLOGY Vol 13 No 12
Volume 13
Issue 12

A 15-year study published in the June 1, 1999, issue of Cancer offers further hope to premenopausal breast cancer patients who might want to bear children. According to the study of 520 women £ 40 years old, pregnancy after breast cancer diagnosis and successful treatment does not increase a patient’s risk for recurrence or death from the disease. This is particularly true for women with local disease at diagnosis.

A 15-year study published in the June 1, 1999, issue of Cancer offers further hope to premenopausal breast cancer patients who might want to bear children. According to the study of 520 women £ 40 years old, pregnancy after breast cancer diagnosis and successful treatment does not increase a patient’s risk for recurrence or death from the disease. This is particularly true for women with local disease at diagnosis.

Of the 53 study women who became pregnant after being diagnosed with breast cancer, 68% delivered one or more live-born infants. The miscarriage rate (24%) among these women was 70% higher than expected, however. Chemotherapy or the radiation used to treat breast cancer may be associated with the increased miscarriage rate. Of the 36 women who gave birth to a live infant, 5 died of their breast cancer. There was a 0.8 chance of death associated with any subsequent pregnancy in this population.

“The results of our study support the growing consensus that subsequent pregnancy does not have an adverse effect on survival after breast carcinoma, particularly among women with local disease,” said study coauthor Priscilla Velentgas, PhD, Department of Biostatistics, University of Washington, Seattle.

Study Protocol and Limitations

Researchers reviewed completed questionnaire, interview, and cancer registry information from 520 western Washington women diagnosed with stage I or II breast cancer between 1983 and 1992. The women had been followed for breast cancer deaths through April 1998. All of the women were 40 years of age or less, premenopausal, had not undergone surgical removal of their reproductive organs, and were not pregnant at the time of their initial breast cancer diagnosis.

In the June 1 issue of Cancer, an editorial commends the current study but also notes its limitations. “[This study] comes at a time when American women are opting for later childbirth and the incidence of breast carcinoma continues to rise in all age groups,” said editorial coauthor Hervy B. Averette, MD, Division of Gynecological Oncology, University of Miami School of Medicine, Florida. Dr. Averette added, “Approximately 25% of women will develop a breast cancer in their premenopausal years and still may wish to bear children. However, a major 1994 study suggested that hormones involved in pregnancy might promote hidden cancer development. That study’s researchers noted that patient survival was better proportionately with up to a 4-year interval between breast cancer diagnosis and subsequent pregnancy. Yet to our knowledge, there are seven published reports implying that subsequent pregnancy after breast carcinoma is safe when corrected for stage of the tumor.”

The editorial also points out the current study’s limitations, such as its retrospective data that are based on “memory of the treating physician, review of hospital records, and/or interview with family members. Furthermore, the potential for selection bias in these retrospective studies is enormous.”

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Related Content